ALBO News and Press, Albireo Pharma Inc. From 06/07/19

Albireo Pharma (NASDAQ: ALBO ) announces positive data from a Phase 2 clinical trial evaluating lead candidate odevixibat (A4250) in patients with three rare liver/bile duct disorders: biliary atresia, Alagille syndrome and progressive familial intrahepatic cholestasis. The results were pr...

BOSTON, June 07, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that clinical data from a Phase 2 study of lead product candidate odevixibat (A4250), a highly potent and s...

BOSTON, May 29, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the following invest...

BOSTON, May 23, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that clinical data and important findings from studies of lead candidate odevixibat (A4250) in biliary...

Market Assessment Albireo (ALBO) is a small-market-cap ($423M), commercial-stage biopharma that was publicly listed through a reverse merger with Biodel in November 2016. Its clinical focus on pediatric-orphan liver therapeutics and the development of novel bile acid modulators, ileal bi...

Albireo Pharma, Inc. (ALBO) Q1 2019 Earnings Conference Call May 09, 2019 10:00 AM ET Company Participants Paul Arndt - Investor Relations Ronald Cooper - President and Chief Executive Officer Patrick Horn - Chief Medical Officer Simon Harford - Chief Financial Officer Confe...

Albireo Pharma (NASDAQ: ALBO ): Q1 GAAP EPS of -$1.39 misses by $0.04 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Odevixibat Phase 3 PEDFIC 1 PFIC trial continues to enroll as planned Initiation of additional cohort of PFIC patients in PEDFIC 2 extension trial announced Odevixibat pivotal trial in biliary atresia on track to begin H2 2019 IND cleared to initiate elobixibat Phase 2 trial in NASH ...

BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10 a.m. EDT on May 9, ...

An open-label Phase 2 clinical trial evaluating Albireo Pharma's ( ALBO -3.9% ) lead candidate A4250 in pediatric Alagille syndrome and biliary atresia patients for the treatment of cholestasis (restricted or blocked bile flow) showed a positive effect . The results were presented at The ...